BioCardia
Biocardia Home Helix Biotherapeutic Delivery Morph Access Innovations About Us
Biocardia Enabling Biointerventional Cardiology & Redefining Vascular Access Biocardia Enabling Biointerventional Cardiology & Redefining Vascular Access
BioCardia is a biotherapeutic platform and product company based on fully developed medical device technologies.
Learn More
CORE BUSINESSES

BioCardia is engaged in two core businesses:

Helix Biotherapeutic Delivery offers a catheter system for the local delivery of cells, gene, and protein therapeutics to the heart.

Morph Access Innovations develops advanced catheter products for interventional medicine.

HELIX NEWS

November 18, 2013
Phase II TAC-HFT Trial Shows Excellent Safety Profile, Suggests Efficacy, for Transendocardial Delivery of Two Types of Autologous Cells for Ischemic Heart Failure

October 28, 2013
Juventas Therapeutics completes enrollment of Phase II STOP-HF study of JVS-100 in patients with symptomatic heart failure

more newsmore publications

 MORPH NEWS

March 2011
AccessPro Steerable Introducer Article in March 2011 Endovascular Today by Dr. Frank Arko et al.

January 6, 2011
BioCardia elects Jay M. Moyes to Board of Directors

November 18, 2010
BioCardia Announces CE Mark Approval


more newsmore publications

 

 view Animation explaining Helical Infusion Systemview Morph Certification Training Video
© 2007-2013 BioCardia, Inc. | 125 Shoreway Road, Suite B, San Carlos, CA 94070 | (800) 624-1179 | (650) 226-0120 | Fax: (650) 631-3731 |

This Site is protected by United States and international copyright and trademark laws. The contents of the Site may not be distributed, modified, reproduced, or used, in whole or in part, without the prior written consent of BioCardia. Any copies of material or other content provided through the Site must include the same copyright and other proprietary notices that appear with the material or content.